Roche will acquire Poseida Therapeutics, building on a partnership for CAR T-cell therapies in development for MS and other ...

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel ...

A novel CAR T-cell therapy has benefitted patients with relapsed acute lymphoblastic leukemia, showing high response rates in ...

In a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset ...

A small trial used designer CAR T cells to reboot the immune systems of patients with three autoimmune diseases, but it's ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel ...

‘Poly-refractory’ disease affects 2.7% of patients with rheumatoid arthritis (RA) who have failed different groups of biologic disease-modifying antirheumatic drugs (b-DMARDS) and targeted synthetic ...

SCG has revealed late-breaking data outcomes from the Phase I clinical trial of autologous hepatitis B virus (HBV)-specific T ...